Module 2: Radiopharmaceutical Chemistry
Module 2 forms the scientific and practical core of the CAS ETH Rad. Pharm. Focusing on radiopharmaceutical chemistry, it incorporates hands-on work in biochemical, pharmaceutical, radiochemical and GMP laboratories – linking radiotracer development with production and quality control for preclinical research and clinical use. It is delivered by ETH Zurich and the Paul Scherrer Institute (PSI), which cover the entire bench-to-bedside pathway with their complementary expertise and infrastructure.
Expand your knowledge of radiopharmaceutical chemistry
After completing Module 2, you will know how to apply the principles of radionuclide production, radionuclide generator systems and radiolabelling. You will also have learned how to design and characterise radiolabelled peptides and antibodies using in vitro and in vivo methods. In addition, you will be able to perform key production and quality-control procedures in radiochemical, pharmaceutical and GMP laboratories and understand how to evaluate the translation of radiotracers from preclinical development to clinical use.
ETH Zurich is laying the groundwork to enable it to anticipate future technological developmentsand social challenges at an early stage and to develop solutions to them. To help achieve this, it is strengthening national and international cooperation in research and education.
external page PSI is Switzerland’s largest research institute for natural and engineering sciences, with around 2,300 employees and an annual budget of CHF 450 million. As part of the ETH domain, it conducts cutting-edge research in future technologies, energy and climate, health innovation, and the fundamentals of nature. PSI develops and operates globally unique large-scale research facilities that are used by more than 2,000 researchers from Switzerland and abroad every year. Through close collaboration with industry, technology transfer and spin-offs, PSI makes an important contribution to Switzerland’s innovative strength and trains highly qualified specialists for science and industry. PSI also operates Switzerland’s only proton therapy facility, providing highly targeted treatment for specific types of cancer.
- Radionuclide production and generator systems
- Kits and pitfalls
- In vitro- and in vivo-characterisation of radiolabelled peptides and antibodiesChemistry of Tc, Re and other radiometals
- Chemistry of C-11, F-18 and other halogen isotopes
- Animal and in vitro models
- Workshops discussing practical aspects of bringing radiotracers from bench-to-bedside
- Hands-on experience of radiolabelling, affinity measurements and QC of antibodies
- Use of 99mTc-kits including QC
- The use of 68Ge/68Ga-generator and hands-on experience of 68Ga-radiolabelling of peptides including QC under GMP conditions
- Hands-on C-11 and F-18-radiolabelling of molecules under research conditions
- In vitro/preclinical characterisation of PET radiopharmaceuticals
Module 2
For further details, please see the module programme for 2028.
31 January - 11 February 2028
11:00 am (CET): written exam on first day of module
The course takes place at the Institute of Pharmaceutical Sciences at the ETH Zurich and is hosted by Radiopharmaceutical Sciences.
Participants are kindly asked to organise their own accommodation.
ETH Zurich
Institute of Pharmaceutical Sciences, Postgraduate Studies Pharmacy
Vladimir-Prelog-Weg 4
8093
Zurich
Switzerland
“The CAS ETH Rad. Pharm. enables chemists, biochemists, pharmacists and other professionals to build a shared language and cross-disciplinary skills needed in radiopharmacy.”Professor Roger Schibli, Head of the Center for Radiopharmaceutical Sciences - ETH Zurich & PSI